RUNX2 Promotes Malignant Progression in Glioma

Daisuke Yamada, Koichi Fujikawa, Kenji Kawabe, Takuya Furuta, Mitsutoshi Nakada, Takeshi Takarada

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Glioblastoma (GBM) is the most aggressive and lethal form of brain tumor. However, therapeutic strategies against malignant gliomas have not been completely established. Runt-related transcription factor 2 (Runx2) is an essential gene for skeletal development but its regulatory role in the malignant progression of glioma remains unclear. Here we investigated expression levels of RUNX2 in glioma tissues and its regulatory effects on aberrant growth of glioma cells. RUNX2 mRNA levels were higher in GBM tissues than that of normal brains or low-grade gliomas. RUNX2 protein was detected in five out of seven human GBM cell lines and its level was positively correlated with proliferative capacity. Stable transduction of dominant-negative Runx2 in rat-derived C6 glioma cells not only inhibited the promoter activity containing Runx2 response element, but also decreased mRNA expression levels of Runx2 target genes, such as Mmp13 and Spp1, as well as the proliferative capacity. Furthermore, transient introduction of Runx2-targeted siRNAs into C6 glioma cells significantly decreased mRNA expression levels of Mmp13 and Spp1 and the proliferative capacity. Furthermore, Runx2 knockdown suppressed both Ccnd1 mRNA expression and activation of the Ccnd1 promoter by forskolin, a PKA-activating reagent, in C6 glioma cells. Our results demonstrate that cross-talk between cAMP/PKA signaling and RUNX2 promotes a malignant phenotype of glioma cells.

Original languageEnglish
JournalNeurochemical Research
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Glioma
Messenger RNA
Brain
Genes
Glioblastoma
Tissue
Response Elements
Colforsin
Rats
Tumors
Transcription Factors
Chemical activation
Cells
Essential Genes
Brain Neoplasms
Proteins
Phenotype
Cell Line
Growth

Keywords

  • Glioma
  • Protein kinase A
  • RUNX2

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

RUNX2 Promotes Malignant Progression in Glioma. / Yamada, Daisuke; Fujikawa, Koichi; Kawabe, Kenji; Furuta, Takuya; Nakada, Mitsutoshi; Takarada, Takeshi.

In: Neurochemical Research, 01.01.2018.

Research output: Contribution to journalArticle

Yamada, Daisuke ; Fujikawa, Koichi ; Kawabe, Kenji ; Furuta, Takuya ; Nakada, Mitsutoshi ; Takarada, Takeshi. / RUNX2 Promotes Malignant Progression in Glioma. In: Neurochemical Research. 2018.
@article{3411d8091e8f4551bb6e992961dde142,
title = "RUNX2 Promotes Malignant Progression in Glioma",
abstract = "Glioblastoma (GBM) is the most aggressive and lethal form of brain tumor. However, therapeutic strategies against malignant gliomas have not been completely established. Runt-related transcription factor 2 (Runx2) is an essential gene for skeletal development but its regulatory role in the malignant progression of glioma remains unclear. Here we investigated expression levels of RUNX2 in glioma tissues and its regulatory effects on aberrant growth of glioma cells. RUNX2 mRNA levels were higher in GBM tissues than that of normal brains or low-grade gliomas. RUNX2 protein was detected in five out of seven human GBM cell lines and its level was positively correlated with proliferative capacity. Stable transduction of dominant-negative Runx2 in rat-derived C6 glioma cells not only inhibited the promoter activity containing Runx2 response element, but also decreased mRNA expression levels of Runx2 target genes, such as Mmp13 and Spp1, as well as the proliferative capacity. Furthermore, transient introduction of Runx2-targeted siRNAs into C6 glioma cells significantly decreased mRNA expression levels of Mmp13 and Spp1 and the proliferative capacity. Furthermore, Runx2 knockdown suppressed both Ccnd1 mRNA expression and activation of the Ccnd1 promoter by forskolin, a PKA-activating reagent, in C6 glioma cells. Our results demonstrate that cross-talk between cAMP/PKA signaling and RUNX2 promotes a malignant phenotype of glioma cells.",
keywords = "Glioma, Protein kinase A, RUNX2",
author = "Daisuke Yamada and Koichi Fujikawa and Kenji Kawabe and Takuya Furuta and Mitsutoshi Nakada and Takeshi Takarada",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s11064-018-2626-4",
language = "English",
journal = "Neurochemical Research",
issn = "0364-3190",
publisher = "Springer New York",

}

TY - JOUR

T1 - RUNX2 Promotes Malignant Progression in Glioma

AU - Yamada, Daisuke

AU - Fujikawa, Koichi

AU - Kawabe, Kenji

AU - Furuta, Takuya

AU - Nakada, Mitsutoshi

AU - Takarada, Takeshi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Glioblastoma (GBM) is the most aggressive and lethal form of brain tumor. However, therapeutic strategies against malignant gliomas have not been completely established. Runt-related transcription factor 2 (Runx2) is an essential gene for skeletal development but its regulatory role in the malignant progression of glioma remains unclear. Here we investigated expression levels of RUNX2 in glioma tissues and its regulatory effects on aberrant growth of glioma cells. RUNX2 mRNA levels were higher in GBM tissues than that of normal brains or low-grade gliomas. RUNX2 protein was detected in five out of seven human GBM cell lines and its level was positively correlated with proliferative capacity. Stable transduction of dominant-negative Runx2 in rat-derived C6 glioma cells not only inhibited the promoter activity containing Runx2 response element, but also decreased mRNA expression levels of Runx2 target genes, such as Mmp13 and Spp1, as well as the proliferative capacity. Furthermore, transient introduction of Runx2-targeted siRNAs into C6 glioma cells significantly decreased mRNA expression levels of Mmp13 and Spp1 and the proliferative capacity. Furthermore, Runx2 knockdown suppressed both Ccnd1 mRNA expression and activation of the Ccnd1 promoter by forskolin, a PKA-activating reagent, in C6 glioma cells. Our results demonstrate that cross-talk between cAMP/PKA signaling and RUNX2 promotes a malignant phenotype of glioma cells.

AB - Glioblastoma (GBM) is the most aggressive and lethal form of brain tumor. However, therapeutic strategies against malignant gliomas have not been completely established. Runt-related transcription factor 2 (Runx2) is an essential gene for skeletal development but its regulatory role in the malignant progression of glioma remains unclear. Here we investigated expression levels of RUNX2 in glioma tissues and its regulatory effects on aberrant growth of glioma cells. RUNX2 mRNA levels were higher in GBM tissues than that of normal brains or low-grade gliomas. RUNX2 protein was detected in five out of seven human GBM cell lines and its level was positively correlated with proliferative capacity. Stable transduction of dominant-negative Runx2 in rat-derived C6 glioma cells not only inhibited the promoter activity containing Runx2 response element, but also decreased mRNA expression levels of Runx2 target genes, such as Mmp13 and Spp1, as well as the proliferative capacity. Furthermore, transient introduction of Runx2-targeted siRNAs into C6 glioma cells significantly decreased mRNA expression levels of Mmp13 and Spp1 and the proliferative capacity. Furthermore, Runx2 knockdown suppressed both Ccnd1 mRNA expression and activation of the Ccnd1 promoter by forskolin, a PKA-activating reagent, in C6 glioma cells. Our results demonstrate that cross-talk between cAMP/PKA signaling and RUNX2 promotes a malignant phenotype of glioma cells.

KW - Glioma

KW - Protein kinase A

KW - RUNX2

UR - http://www.scopus.com/inward/record.url?scp=85053034891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053034891&partnerID=8YFLogxK

U2 - 10.1007/s11064-018-2626-4

DO - 10.1007/s11064-018-2626-4

M3 - Article

C2 - 30203400

AN - SCOPUS:85053034891

JO - Neurochemical Research

JF - Neurochemical Research

SN - 0364-3190

ER -